176 related articles for article (PubMed ID: 38423601)
61. Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma.
Mairinger FD; Walter RF; Ting S; Vollbrecht C; Kollmeier J; Griff S; Hager T; Mairinger T; Christoph DC; Theegarten D; Schmid KW; Wohlschlaeger J
Future Oncol; 2014 May; 10(6):995-1005. PubMed ID: 24941985
[TBL] [Abstract][Full Text] [Related]
62. Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
Edakuni N; Ikuta K; Yano S; Nakataki E; Muguruma H; Uehara H; Tani M; Yokota J; Aizawa H; Sone S
Oncol Res; 2006; 16(5):235-43. PubMed ID: 17294804
[TBL] [Abstract][Full Text] [Related]
63. Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.
Riquelme E; Suraokar MB; Rodriguez J; Mino B; Lin HY; Rice DC; Tsao A; Wistuba II
J Thorac Oncol; 2014 Jul; 9(7):998-1007. PubMed ID: 24926545
[TBL] [Abstract][Full Text] [Related]
64. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
Borchert S; Wessolly M; Schmeller J; Mairinger E; Kollmeier J; Hager T; Mairinger T; Herold T; Christoph DC; Walter RFH; Eberhardt WEE; Plönes T; Wohlschlaeger J; Aigner C; Schmid KW; Mairinger FD
BMC Cancer; 2019 Jan; 19(1):108. PubMed ID: 30700254
[TBL] [Abstract][Full Text] [Related]
65. Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients.
Kishimoto T; Fujimoto N; Ebara T; Omori T; Oguri T; Niimi A; Yokoyama T; Kato M; Usami I; Nishio M; Yoshikawa K; Tokuyama T; Tamura M; Yokoyama Y; Tsuboi K; Matsuo Y; Xu J; Takahashi S; Abdelgied M; Alexander WT; Alexander DB; Tsuda H
BMC Cancer; 2019 Dec; 19(1):1204. PubMed ID: 31823764
[TBL] [Abstract][Full Text] [Related]
66. Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.
Ramírez-Salazar EG; Salinas-Silva LC; Vázquez-Manríquez ME; Gayosso-Gómez LV; Negrete-Garcia MC; Ramírez-Rodriguez SL; Chávez R; Zenteno E; Santillán P; Kelly-García J; Ortiz-Quintero B
Exp Mol Pathol; 2014 Dec; 97(3):375-85. PubMed ID: 25236577
[TBL] [Abstract][Full Text] [Related]
67. Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients.
Hylebos M; Op de Beeck K; Pauwels P; Zwaenepoel K; van Meerbeeck JP; Van Camp G
Lung Cancer; 2018 Oct; 124():19-22. PubMed ID: 30268460
[TBL] [Abstract][Full Text] [Related]
68. p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.
Tian K; Bakker E; Hussain M; Guazzelli A; Alhebshi H; Meysami P; Demonacos C; Schwartz JM; Mutti L; Krstic-Demonacos M
J Transl Med; 2018 Oct; 16(1):282. PubMed ID: 30316293
[TBL] [Abstract][Full Text] [Related]
69. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
[TBL] [Abstract][Full Text] [Related]
70. Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia.
Zonca S; Pinton G; Wang Z; Soluri MF; Tavian D; Griffin M; Sblattero D; Moro L
Cell Death Dis; 2017 Feb; 8(2):e2592. PubMed ID: 28151477
[TBL] [Abstract][Full Text] [Related]
71. [Systemic Treatment of Malignant Pleural Mesothelioma].
Nakano T
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
[TBL] [Abstract][Full Text] [Related]
72. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
Muraoka T; Soh J; Toyooka S; Aoe K; Fujimoto N; Hashida S; Maki Y; Tanaka N; Shien K; Furukawa M; Yamamoto H; Asano H; Tsukuda K; Kishimoto T; Otsuki T; Miyoshi S
Lung Cancer; 2013 Dec; 82(3):485-90. PubMed ID: 24168922
[TBL] [Abstract][Full Text] [Related]
73. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
Betti M; Casalone E; Ferrante D; Aspesi A; Morleo G; Biasi A; Sculco M; Mancuso G; Guarrera S; Righi L; Grosso F; Libener R; Pavesi M; Mariani N; Casadio C; Boldorini R; Mirabelli D; Pasini B; Magnani C; Matullo G; Dianzani I
Cancer Lett; 2017 Oct; 405():38-45. PubMed ID: 28687356
[TBL] [Abstract][Full Text] [Related]
74. Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.
Cioce M; Ganci F; Canu V; Sacconi A; Mori F; Canino C; Korita E; Casini B; Alessandrini G; Cambria A; Carosi MA; Blandino R; Panebianco V; Facciolo F; Visca P; Volinia S; Muti P; Strano S; Croce CM; Pass HI; Blandino G
Oncogene; 2014 Nov; 33(46):5319-31. PubMed ID: 24240684
[TBL] [Abstract][Full Text] [Related]
75. Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
Tsao A; Nakano T; Nowak AK; Popat S; Scagliotti GV; Heymach J
Semin Oncol; 2019 Apr; 46(2):145-154. PubMed ID: 31280996
[TBL] [Abstract][Full Text] [Related]
76. [Expression of CD24 gene in human malignant pleural mesothelioma and its relationship with prognosis].
Li B; Zhou CX; Pu YQ; Qiu L; Mei W; Xiong W
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Mar; 41(3):168-176. PubMed ID: 37006141
[No Abstract] [Full Text] [Related]
77. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
Lo Iacono M; Monica V; Righi L; Grosso F; Libener R; Vatrano S; Bironzo P; Novello S; Musmeci L; Volante M; Papotti M; Scagliotti GV
J Thorac Oncol; 2015 Mar; 10(3):492-9. PubMed ID: 25514803
[TBL] [Abstract][Full Text] [Related]
78. Blood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: The EPIC prospective cohort.
Allione A; Viberti C; Cotellessa I; Catalano C; Casalone E; Cugliari G; Russo A; Guarrera S; Mirabelli D; Sacerdote C; Gentile M; Eichelmann F; Schulze MB; Harlid S; Eriksen AK; Tjønneland A; Andersson M; Dollé MET; Van Puyvelde H; Weiderpass E; Rodriguez-Barranco M; Agudo A; Heath AK; Chirlaque MD; Truong T; Dragic D; Severi G; Sieri S; Sandanger TM; Ardanaz E; Vineis P; Matullo G
Int J Cancer; 2023 Feb; 152(4):725-737. PubMed ID: 36305648
[TBL] [Abstract][Full Text] [Related]
79. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
[TBL] [Abstract][Full Text] [Related]
80. Clinical significance of serum DRAM1 mRNA, ARSA mRNA, hsa-miR-2053 and lncRNA-RP1-86D1.3 axis expression in malignant pleural mesothelioma.
Matboli M; Shafei AE; Ali MA; Gaber AI; Galal A; Tarek O; Marei M; Khairy E; El-Khazragy N; Anber N; Abdel-Rahman O
J Cell Biochem; 2019 Mar; 120(3):3203-3211. PubMed ID: 30362153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
